| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.
|
Proc Natl Acad Sci U S A
|
2002
|
5.81
|
|
2
|
Genomic analysis of the host response to hepatitis C virus infection.
|
Proc Natl Acad Sci U S A
|
2002
|
5.28
|
|
3
|
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.
|
J Virol
|
2003
|
4.42
|
|
4
|
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
|
Proc Natl Acad Sci U S A
|
2003
|
3.40
|
|
5
|
Hepatitis E virus.
|
Rev Med Virol
|
2003
|
3.34
|
|
6
|
Genomic analysis of the host response to hepatitis B virus infection.
|
Proc Natl Acad Sci U S A
|
2004
|
3.16
|
|
7
|
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
|
Proc Natl Acad Sci U S A
|
2007
|
2.69
|
|
8
|
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994.
|
J Infect Dis
|
2009
|
2.62
|
|
9
|
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
|
Proc Natl Acad Sci U S A
|
2005
|
2.42
|
|
10
|
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury.
|
Gastroenterology
|
2011
|
2.25
|
|
11
|
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.
|
Proc Natl Acad Sci U S A
|
2002
|
2.04
|
|
12
|
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.
|
Gastroenterology
|
2004
|
2.01
|
|
13
|
Hepatitis E.
|
N Engl J Med
|
2012
|
1.99
|
|
14
|
Chimpanzees as an animal model for human norovirus infection and vaccine development.
|
Proc Natl Acad Sci U S A
|
2010
|
1.96
|
|
15
|
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees.
|
Proc Natl Acad Sci U S A
|
2004
|
1.96
|
|
16
|
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences.
|
Proc Natl Acad Sci U S A
|
2003
|
1.93
|
|
17
|
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus.
|
Proc Natl Acad Sci U S A
|
2008
|
1.83
|
|
18
|
Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant.
|
Proc Natl Acad Sci U S A
|
2011
|
1.81
|
|
19
|
Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark.
|
Clin Infect Dis
|
2008
|
1.75
|
|
20
|
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection.
|
J Virol
|
2009
|
1.71
|
|
21
|
In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein.
|
J Virol
|
2004
|
1.66
|
|
22
|
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.
|
J Virol
|
2007
|
1.61
|
|
23
|
Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.
|
J Virol
|
2004
|
1.58
|
|
24
|
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.
|
J Virol
|
2010
|
1.55
|
|
25
|
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.
|
Hepatology
|
2008
|
1.55
|
|
26
|
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics.
|
Hepatology
|
2011
|
1.54
|
|
27
|
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma.
|
Proc Natl Acad Sci U S A
|
2004
|
1.53
|
|
28
|
The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques.
|
J Virol
|
2005
|
1.50
|
|
29
|
Running like water--the omnipresence of hepatitis E.
|
N Engl J Med
|
2004
|
1.49
|
|
30
|
ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro.
|
J Virol
|
2006
|
1.47
|
|
31
|
High prevalence of hepatitis E antibodies in pregnant Egyptian women.
|
Trans R Soc Trop Med Hyg
|
2005
|
1.40
|
|
32
|
Thermal stability of hepatitis E virus.
|
J Infect Dis
|
2005
|
1.39
|
|
33
|
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
|
Hepatology
|
2005
|
1.38
|
|
34
|
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
|
PLoS Pathog
|
2012
|
1.35
|
|
35
|
Hidden danger: the raw facts about hepatitis E virus.
|
J Infect Dis
|
2010
|
1.35
|
|
36
|
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain.
|
J Virol
|
2008
|
1.33
|
|
37
|
Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif.
|
J Virol
|
2010
|
1.32
|
|
38
|
Dynamics of hepatitis B virus clearance in chimpanzees.
|
Proc Natl Acad Sci U S A
|
2005
|
1.29
|
|
39
|
Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay.
|
J Gen Virol
|
2006
|
1.29
|
|
40
|
Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody.
|
J Virol
|
2007
|
1.28
|
|
41
|
Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period.
|
J Virol
|
2011
|
1.28
|
|
42
|
B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure.
|
Proc Natl Acad Sci U S A
|
2010
|
1.26
|
|
43
|
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.
|
J Virol
|
2008
|
1.26
|
|
44
|
Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.
|
J Virol
|
2004
|
1.25
|
|
45
|
Apolipoprotein c1 association with hepatitis C virus.
|
J Virol
|
2008
|
1.24
|
|
46
|
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.
|
Hepatology
|
2011
|
1.23
|
|
47
|
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.
|
Infect Immun
|
2009
|
1.22
|
|
48
|
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.
|
J Infect Dis
|
2010
|
1.21
|
|
49
|
Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.
|
J Virol
|
2004
|
1.19
|
|
50
|
Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles.
|
J Virol
|
2007
|
1.16
|
|
51
|
An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4.
|
Vaccine
|
2004
|
1.15
|
|
52
|
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles.
|
Clin Vaccine Immunol
|
2009
|
1.15
|
|
53
|
Epidemic of hepatitis E in a military unit in Abbotrabad, Pakistan.
|
Am J Trop Med Hyg
|
2002
|
1.15
|
|
54
|
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.
|
Proc Natl Acad Sci U S A
|
2012
|
1.15
|
|
55
|
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding.
|
Proc Natl Acad Sci U S A
|
2009
|
1.14
|
|
56
|
High prevalence of hepatitis E antibodies among Danish prisoners and drug users.
|
J Med Virol
|
2002
|
1.14
|
|
57
|
Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities.
|
Trans R Soc Trop Med Hyg
|
2005
|
1.12
|
|
58
|
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.
|
J Infect Dis
|
2011
|
1.10
|
|
59
|
In vitro and in vivo mutational analysis of the 3'-terminal regions of hepatitis e virus genomes and replicons.
|
J Virol
|
2005
|
1.09
|
|
60
|
In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.
|
J Virol
|
2007
|
1.08
|
|
61
|
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.
|
Proc Natl Acad Sci U S A
|
2012
|
1.07
|
|
62
|
A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.
|
Vaccine
|
2005
|
1.06
|
|
63
|
Spatial configuration of hepatitis E virus antigenic domain.
|
J Virol
|
2010
|
1.05
|
|
64
|
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta.
|
Clin Infect Dis
|
2006
|
1.04
|
|
65
|
Functional analyses of GB virus B p13 protein: development of a recombinant GB virus B hepatitis virus with a p7 protein.
|
Proc Natl Acad Sci U S A
|
2006
|
1.01
|
|
66
|
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.
|
Proc Natl Acad Sci U S A
|
2012
|
1.01
|
|
67
|
Hepatitis E virus seroprevalence in the United States: no easy answers.
|
Hepatology
|
2014
|
1.00
|
|
68
|
Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.
|
J Virol
|
2013
|
0.99
|
|
69
|
Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine.
|
Vaccine
|
2003
|
0.99
|
|
70
|
Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences.
|
J Virol
|
2010
|
0.99
|
|
71
|
Prevalence study of antibody to ratborne pathogens and other agents among patients using a free clinic in downtown Los Angeles.
|
J Infect Dis
|
2002
|
0.98
|
|
72
|
The half-life of hepatitis B virions.
|
Hepatology
|
2006
|
0.98
|
|
73
|
Positive reactions on Western blots do not necessarily indicate the epitopes on antigens are continuous.
|
Immunol Cell Biol
|
2006
|
0.98
|
|
74
|
Hepatitis E virus seroprevalence in the National Health and Nutrition Examination Survey: facts trump opinion.
|
Hepatology
|
2015
|
0.98
|
|
75
|
Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays.
|
J Med Virol
|
2008
|
0.97
|
|
76
|
The challenge of developing a vaccine against hepatitis C virus.
|
J Hepatol
|
2002
|
0.94
|
|
77
|
Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8⁺ T cells in early viral evolution.
|
J Virol
|
2011
|
0.93
|
|
78
|
Using improved technology for filter paper-based blood collection to survey wild Sika deer for antibodies to hepatitis E virus.
|
J Virol Methods
|
2007
|
0.92
|
|
79
|
Identification of VP1/2A and 2C as virulence genes of hepatitis A virus and demonstration of genetic instability of 2C.
|
J Virol
|
2002
|
0.92
|
|
80
|
Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.
|
Proc Natl Acad Sci U S A
|
2013
|
0.91
|
|
81
|
Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure.
|
J Struct Biol
|
2012
|
0.89
|
|
82
|
Mouse monoclonal antibodies to anthrax edema factor protect against infection.
|
Infect Immun
|
2011
|
0.88
|
|
83
|
Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.
|
Proc Natl Acad Sci U S A
|
2010
|
0.88
|
|
84
|
Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.
|
Vaccine
|
2002
|
0.88
|
|
85
|
Genotypic characterization of symptomatic hepatitis E virus (HEV) infections in Egypt.
|
J Clin Virol
|
2009
|
0.87
|
|
86
|
Hepatitis E.
|
Pediatr Infect Dis J
|
2007
|
0.86
|
|
87
|
Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins.
|
J Gen Virol
|
2009
|
0.85
|
|
88
|
Quantification of hepatitis B virus genomes and infectivity in human serum samples.
|
Transfusion
|
2006
|
0.85
|
|
89
|
DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice.
|
Vaccine
|
2002
|
0.84
|
|
90
|
Immunity against the GBV-B hepatitis virus in tamarins can prevent productive infection following rechallenge and is long-lived.
|
J Med Virol
|
2008
|
0.84
|
|
91
|
Hepatitis E virus ORF2 protein over-expressed by baculovirus in hepatoma cells, efficiently encapsidates and transmits the viral RNA to naïve cells.
|
Virol J
|
2011
|
0.83
|
|
92
|
A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo.
|
Proc Natl Acad Sci U S A
|
2006
|
0.82
|
|
93
|
Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
|
Intervirology
|
2006
|
0.81
|
|
94
|
Occult hepatitis B virus infection in chacma baboons, South Africa.
|
Emerg Infect Dis
|
2013
|
0.80
|
|
95
|
Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species.
|
J Virol
|
2011
|
0.80
|
|
96
|
Long PCR methodology.
|
Methods Mol Biol
|
2003
|
0.79
|
|
97
|
Long PCR amplification of large fragments of viral genomes: a technical overview.
|
Methods Mol Biol
|
2003
|
0.78
|
|
98
|
Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively.
|
J Infect Dis
|
2011
|
0.77
|
|
99
|
Chronic hepatitis E with neurologic manifestations and rapid progression of liver fibrosis in a liver transplant recipient.
|
Dig Dis Sci
|
2013
|
0.77
|
|
100
|
Isolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization.
|
PLoS One
|
2013
|
0.76
|
|
101
|
Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors.
|
Transfusion
|
2014
|
0.75
|
|
102
|
Persistent human hepatitis B virus infection in cynomolgus monkeys: a novel animal model in the search for a cure?
|
Hepatology
|
2013
|
0.75
|
|
103
|
Impact.
|
Natl Med J India
|
2014
|
0.75
|